In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In the upcoming […]
Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical. In the upcoming webinar in the series of summer educational webinars, […]
NIH alone awards roughly $5.8B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well. In the upcoming webinar in the series of summer educational webinars, FreeMind’s VP, Ayal Ronen, will discuss key […]
The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA etc. this is a funding force no one in the field can afford to ignore. In our first Webinar, FreeMind’s VP Ayal Ronen will discuss Biodefense and Infectious Diseases funding opportunities […]
Lucas Laursen Nature 486, 559-561 (2012) doi:10.1038/nj7404-559a Published online 27 June 2012 This article was originally published in the journal Nature Some consultants offer to help researchers to find and secure grants. But scientists should carefully consider whether and how a consultant is worth the time and expense. Read article online The e-mails were arriving in […]
Non dilutive R&D funding – mainly multibillion programs of Federal agencies – has become a major player in the life science finance industry. Today more than ever, NIH, DOD, NSF, CDC and dozens of other agencies, both federal and private, support biological and medical preclinical and clinical activities in all fields and scopes of research […]
Over the past decade, the United States government has allocated nearly $55 billion on preparing the nation against biological threats. The Obama administration has maintained that momentum with a total biodefense budget of $6.05 billion for FY2012, going primarily to the NIH and DOD. Additional civilian biodefense funds have been budgeted to the DHS, USDA, […]
One of the most common misperceptions relating to non-dilutive funding for life science R&D is that the SBIR/STTR program is the main and even only funding resource available for the life science industry. Companies and investors alike must know that although it is an important and sometimes relevant program, the SBIR/STTR program is a small, […]
Writing proposals for Federal grants is a time consuming task that requires much planning and administration. This process typically takes 3-6 weeks to complete for a standard high quality application; more complex applications may take longer. However, the brief periods often allotted between release of a funding opportunity announcement and its deadline, as well as […]